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Abstract
Somatic mutations or reduced expression of the von Hippel-Lindau (VHL) tumor suppressor occurs in the majority of the
clear cell renal cell carcinoma (ccRCC) and is a causal factor for the pathogenesis of ccRCC. pVHL was reported to suppress
the oncogenic activity of Epidermal Growth Factor Receptor (EGFR) by reducing the expression of the EGFR agonist TGF-a
and by reducing the translation efficiency of EGFR itself. Furthermore, it was reported that pVHL down-regulates activated
EGFR by promoting efficient lysosomal degradation of the receptor. These modes of negative regulation of EGFR by pVHL
were dependent on Hypoxia Inducible Factor (HIF). In this study, we report that HIF was not the only factor stabilizing the
activated EGFR in VHL-deficient ccRCC cells. Down-regulation of endogenous HIF in these cells had little effect on the
turnover rates of the activated EGFR. Furthermore, neither pretreatment with lysomomal inhibitors pretreatment nor down-
regulation of c-Cbl, a major E3 ubiquitin ligase that targets the activated EGFR for lysosomal degradation, significantly
increased the stabilities of EGFR in VHL-expressing ccRCC cells. In contrast, pretreatment with proteasomal inhibitors
extended EGFR lifetime and led to similar EGFR half-lives in VHL-expressing and VHL-deficient ccRCC cells. Down-regulation
of c-Cbl in VHL-deficient ccRCC cells revealed that the c-Cbl and pVHL collaborated to down-regulate the activated EGFR.
Finally, we found that pVHL promoted the poly-ubiquitylation of the activated EGFR, and this function was c-Cbl-
independent. Thus these results indicate that pVHL limits EGFR signaling by promoting c-Cbl-independent poly-
ubiquitylation of the activated receptor, which likely results in its degradation by proteasome.
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Introduction
Approximately 75% of kidney cancers are characterized as clear
cell renal cell carcinoma (ccRCC). von Hippel-Lindau (VHL)
tumor suppressor gene inactivation plays a causal role in the
pathogenesis of ccRCC. Approximately 70% of sporadic ccRCC
tumors have biallelic inactivation of VHL due to either mutation,
deletion, or hypermethylation of the promoter that reduces VHL
expression [1,2]. Inherited germline mutations in VHL predispose
hereditary kidney cancer patients, to earlier onset bilateral kidney
cancer than sporadic kidney cancer patients, since the loss of the
remaining wild type allele occurs more readily than the loss of two
alleles. pVHL, the protein product of the VHL tumor suppressor
gene, is responsible for substrate recognition by an E3 ubiquitin
ligase complex that consists of pVHL, CUL2, Elongin B and C,
and Rbx1 [3]. This complex adds poly-ubiquitin chains onto the a
subunits of the heterodimeric transcription factor hypoxia-
inducible factor (HIF), leading to proteasome-mediated degrada-
tion of HIF [4]. pVHL is also involved in HIF-independent
biological processes including NF-kB activity inhibition [5],
maintenance of chromosome stability [6], cilia production [7],
and stabilization of RNA polymerase II subunit 1 [8].
The HIF transcription factor is composed of two subunits: the
oxygen-sensitive a subunits (HIF1a, HIF2a, and HIF3a) and the
constitutively expressed HIF1b subunit (also called the arylhy-
drocarbon nuclear translocator [ARNT]) [9]. pVHL only binds to
HIFa if one of two prolyl residues is hydroxylated by members of
the EglN family (also called PHDs or HPHs) [10,11,12,13]. These
enzymes need molecular oxygen, Fe(II) and 2-oxo-glutarate for
proper function. Under normal oxygen tension (normoxia), the a
subunits of HIF are prolyl-hydoxylated, poly-ubiquitylated and
destroyed by proteasome. During oxygen deprivation (hypoxia),
the a subunits are not prolyl-hydroxylated, escape recognition by
pVHL and evade degradation, and heterodimerize with HIF1b.
The HIF complex enters the nucleus and regulates the expression
of hundreds of target genes by binding to hypoxia-response
elements (HRE) [14]. Activation of HIF leads to dramatic changes
in cellular physiology: a metabolic shift to anerobic glycolysis,
increased secretion of pro-angiogenesis factors, remodeling of the
extracellular matrix, and resistance to apoptosis and increased
mobility. These changes help the cells to cope with the short-term
and long-term consequences of oxygen deprivation, a form of
environmental stress. HIF is constitutively activated in the VHL-
defective ccRCC tumors despite the fact that they are well-
oxygenated, since enhanced angiogenesis as a result of increased
secretion of pro-angiogenesis factors is a prominent feature of
ccRCC. In pre-clinical models of ccRCC, HIF suppression is
necessary and sufficient for VHL-dependent suppression of tumor
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23936growth [15] [16,17]. This suggests that inhibiting the activities of
HIF or its critical target genes is clinically important for treatment
of ccRCC. In keeping with the pre-clinical models, drugs that
inhibit the kinase activity of the receptors for Vascular Endothelial
Growth Factor (VEGF), a critical HIF target gene, have been
proved to be clinically effective and have become major
therapeutic agents for treating kidney cancer [18].
It is known that HIF can activate EGFR to promote tumor
growth [19,20]. In VHL-defective ccRCC cells, HIF2a induces
expression of transforming growth factor-a (TGF-aan agonist to
EGFR, and stimulates cell proliferation through an autocrine loop
[19]. At the same time, constitutively active HIF2a also enhances
the efficiency of EGFR mRNA translation [20]. Increased EGFR
expression and elevated TGF-a collectively promote autonomous
growth (cellular growth in the absence of stimulating growth
factors), a hallmark of cancer. Stable suppression of EGFR by
shRNA prevents serum-free growth of VHL-defective ccRCC cells
in vitro, and retards the tumor growth of these cells for extended
periods in xenograft models, without affecting HIF2afunctions
[21,22]. This indicates that the EGFR is critical for the
tumorigenesis of VHL-defective ccRCC cells and is a credible
therapeutic target in kidney cancer.
EGFR is implicated in the development of many human
cancers, as activating mutations of EGFR have been identified in
human glioblastoma, non-small cell lung carcinomas (NSCLC),
and colon cancer. Also, inhibitors of EGFR kinase activity elicit
cell death and tumor shrinkage in NSCLC patients with certain
EGFR mutations [23]. EGFR consists of an extracellular region
with two ligand-binding domains, an extracellular juxta-mem-
brane region, a hydrophobic trans-membrane domain, a cyto-
plasmic tyrosine kinase domain and c-terminal tyrosine residues
that are sites of receptor phosphorylation. Upon ligand binding,
receptors homo- or hetero-dimerize, trans-phosphorylate the c-
terminal tyrosine residues, recruit signaling molecules to these
phosphorylated residues and activate downstream effectors and
biological responses [24]. As Ras/Raf/MEK/ERK and PI3K/
PDK1/Akt1 are two major downstream effector pathways of
activated EGFR that promote both cellular proliferation and
resistance to apoptosis [25], failure to turn off the activated EGFR
can drive oncogenesis.
Endocytosis and lysosome-mediated degradation are major
mechanisms to down-regulate the activated EGFR. The ubiquitin
ligase c-Cbl ubiquitylates phosphorylated EGFR [26]. c-Cbl binds
to EGFR either directly to phosphorylated Y1045 [27] or through
its association with another EGFR-interacting protein Grb2 [28].
Ubiquitylation is sufficient [29] but not necessary [30] for its
endocytosis, because multiple redundant mechanisms participate
in the endocytosis of activated EGFR [31]. Interestingly, although
the ubiquitylation of EGFR is dispensable for endocytosis, it is
absolutely required for the efficient turnover of the EGFR protein
after its activation [30]. Endocytosed EGFR moves from early
endosome to the multi-vesicular body before it is finally sorted to
lysosome for degradation [32]. Controversy exists on the modes of
the EGFR ubiquitylation, as EGFR has been reported to become
both mono-ubiquitylated and poly-ubiquitylated. c-Cbl promotes
mono-ubiquitylation on multiple lysine residues of EGFR, which is
sufficient for EGFR endocytosis and degradation [29,33],
However, mass-spectrometric and western blot analyses have
suggested that a fraction of activated EGFR is poly-ubiquitylated
[34,35]. Currently, however, no specific E3 that promotes poly-
ubiquitylation of the activated EGFR has been identified.
Recently it was reported that pVHL was essential for the
clearance of activated EGFR [36]. The proposed mechanism was
that constitutively active HIF suppressed the expression of
Rabaptin-5 at the transcriptional level. As Rabaptin-5 was critical
for Rab5-mediated endosome fusion, reduced expression of
Rabaptin-5 led to delayed EGFR sorting to the late endosome
and lysosome, hence retarding degradation. This explanation
predicted that delayed turnover of activated EGFR in VHL-
defective ccRCC cells was due to high endogenous levels of HIF a
subunits. In this study, however, we report that endogenous HIF
was not the only cause of delayed EGFR turnover in VHL-
defective ccRCC cells. Furthermore, we found that down-
regulation of the activated EGFR in these cells was likely mediated
by both proteasomal and lysosomal degradation. In addition, loss
of both c-Cbl and VHL had an additive effect on EGFR stability,
suggesting that these ubiquitin ligases collaborated to down-
regulate activated EGFR. Finally, we found that pVHL promoted
the poly-ubiquitylation of the activated EGFR, and this persisted
in the absence of c-Cbl. Thus in ccRCC cells, pVHL promotes the
poly-ubiquitylation of the activated EGFR that is independent of
c-Cbl, and this leads to proteasomal degradation of activated
EGFR. In VHL-defective ccRCC cells, the prolonged signaling of
the activated EGFR likely contributes to tumor growth.
Results
Activated EGFR had higher stability in VHL-deficient cells
than in VHL-expressing ccRCC cells
Ubiquitylation is essential for the down-regulation of activated
EGFR [30,35]. In cells depleted of c-Cbl, activated EGFR is still
ubiquitylated and degraded, albeit at a lower rate than in control cells
[37], suggesting that other E3 ubiquitin ligases contributes to EGFR
ubiquitylation and down-regulation. As pVHL is part of an E3
ubiquitin ligase complex that poly-ubiquitylates its targets and
promotes their degradation, we explored whether pVHL participates
in EGFR turnover. Wecompared the stabilities of activated EGFR in
isogenic 786-O ccRCC cells either reconstituted with VHL (786-
VHL) or expressing the empty plasmid (786-mock). The EGFR half-
life was about 1 hour (h) in 786-VHL cells but approximately 3 h in
786-mock cells (Fig. 1A). The EGFR half-lives were determined by
how long it took for activated EGFR to reach 50% of its starting level.
As an indicator of prolonged EGFR activation, both the phospho-Akt
and the phospho-Erk signals lasted longer in 786-mock cells than in
786-VHL cells after EGF stimulation (Fig. 1A).
To confirm that the difference in the stabilities of the EGFR was
not limited to just one pair of ccRCC cells, we examined EGFR
stabilities in another isogenic pair of ccRCC cells: A498-VHL
(VHL reconstituted) and A498-mock (mock transfected). We
obtained essentially the same result: The EGFR half-life was about
1.6 h in A498-VHL cells but approximately 3.2 h in A498-mock
cells (Fig. 1B). To eliminate the influence of gene transcription and
protein translational efficiency on EGFR turnover, we performed
the same comparison between VHL-expressing and VHL-
deficient cells pretreated with the translational inhibitor cyclohex-
imide. We again observed that EGFR exhibited higher stability in
VHL-deficient 786-O or A498 cells than in their VHL-
reconstituted counterparts (Fig. S1A and S1B). As no new EGFR
was produced after translational inhibition, the longer life-time of
activated EGFR VHL-deficient cells was due to enhanced protein
stability in these cells compared to their VHL-expressing
counterparts. While we were carrying out our studies, another
group reported the same phenomenon independently [36].
HIF was not the only factor that stabilized activated EGFR
in VHL-deficient ccRCC cells
786-O ccRCC cells express only HIF2a, not HIF1a [38].
Although over-expressed HIF2a increased the stability of
pVHL Promotes Poly-Ubiquitylation of EGFR
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intrinsically higher levels of endogenous HIF2a in 786-mock cells
were the major cause of stabilization of activated EGFR in these
cells. To critically assess the relative contribution of endogenous
HIF2a, we stably suppressed the expression of HIF2a, and as a
result its target GLUT1, with two shRNA constructs (HIF2a-566
and HIF2a-1631) against HIF2a. We thereby reduced HIF2a
and consequently, the HIF-target GLUT1 levels close to those
observed in 786-VHL cells (Fig. 2A). The half-lives of activated
EGFR were measured the same way as in Fig. 1A. HIF2a
suppression in 786-VHL cells did not change the half-lives of
activated EGFR (approximately 1.2 h) (Fig. 2B and 2D).
Interestingly, the very successful HIF2a suppression in 786-mock
cells did not significantly reduce the half-lives of activated EGFR
either (Fig. 2C and 2D). The EGFR half-lives in 786-mock cells
expressing either SCR or HIF2a shRNA sequences were all
.3 h, and no statistically significant differences between the
degradation curves were found. Consistent with this, hypoxia
mimetics DFO or CoCl2 that successfully increased the
expression of endogenous HIF2a and its target GLUT1 in 786-
VHL cells also failed to significantly increase the stability of
activated EGFR in these cells (Fig. S2). This suggested that in
786-mock cells endogenous HIF2a was not the only factor
stabilizing activated EGFR.
Proteasome inhibitors prevented degradation of
activated EGFR in both 786-VHL and 786-mock cells,
while lysosome inhibitors only stabilized activated EGFR
in 786-mock cells
Poly-ubiquitylation and proteasome-mediated degradation of the
activated EGFR is not a well-accepted mechanism of EGFR down-
regulation [39,40]. However, disruption of either ubiquitylation or
proteasome functions by a temperature sensitive mutant of the
ubiquitin activating enzyme E1 or by inhibitors has been shown to
block degradation of activated EGFR to some degree [37,41]. We
investigated whether lysosomal and proteasomal degradation
regulated the stabilities of the activated EGFR in 786-VHL and
786-mock cells by pretreating the cells with the lysosome inhibitors
NH4Cl or chloroquine, or proteasome inhibitors MG132 or
Bortezomib. Twenty-four hours pretreatment of the cells with
NH4ClslightlyreducedthematureformofCathepsinD,alysosomal
aspartyl protease, in both 786-VHL and 786-mock cells, and
chloroquine had a much greater effect (Fig. 3A). This suggested that
the lysosome was successfully inhibited [42]. In contrast, pretreat-
ment with MG132 or Bortezomib for two hours did not decrease the
levels of the mature form of Cathepsin D. Instead they significantly
increased the poly-ubiquitylated signals in the lysates, showing that
the proteasome function was blocked so the ubiquitylated protein
couldnotbedegraded(Fig.3A).Surprisingly,neitherofthelysosome
Figure 1. Activated EGFR had higher stability in VHL-deficient ccRCC cells than in VHL-expressing ccRCC cells. A. Renal carcinoma 786-
O cells transfected to produce wild type HA-VHL (786-VHL) or with an empty plasmid (786-mock) were starved for two hours in serum free DMEM
media before addition of 30 ng/ml EGF. Total cell lysates were prepared at indicated time points and immunoblotted with the indicated antibodies.
Anti-HA blot detected HA-VHL. B. The EGFR signals in Fig. 1A were normalized over Vinculin via densitometry and plotted over time. Means and SDs
of three separate experiments were shown. * P,0.05; ** P,=0.001. C. The same experiment in Fig. 1A was repeated with human renal carcinoma
A498 cell lines with or without HA-VHL. D. Graphic representation of Fig. 1C. * P,0.05; ** P,=0.001.
doi:10.1371/journal.pone.0023936.g001
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in the 786-VHL cells: No pretreatment: 1.3 h; NH4Cl, 1.5 h;
chloroquine, 1.7h (Fig. 3B, 3C, 3D, 3E, 3F, and 3G). Instead, both
lysosome inhibitors significantly stabilized the activated EGFR in
VHL-deficient cells; The half-life of activated EGFR in untreated
786-mock was 3 h, while in NH4Cl- or chloroquine- treated 786-
mock cells the activated EGFR was not degraded during the
experiment (Fig. 3B, 3C, 3D, 3E, 3F, and 3G). The pretreament of
the ccRCC cells with proteasome inhibitors, however, abolished the
stability differences of the activated EGFR between the 786-VHL
and 786-mock cells: the activated EGFR was not degraded during
the experiment (Fig.3B,3C,3H,3I, 3J, and3K).Thissuggestedthat
the faster turnover of activated EGFR in VHL-expressing ccRCC
cells was more dependent on proteasome than on lysosome, and
both proteasome and lysosome were important in degrading
activated EGFR in VHL-deficient ccRCC cells.
c-Cbl suppression only significantly stabilized activated
EGFR in VHL-deficient cells but not in VHL-expressing
cells
c-Cbl is the major E3 ubiquitin ligase to target activated
EGFR. C-Cbl binds to tyrosyl phosphorylated EGFR and
mono-ubiquitylates the receptor, leading to endocytosis and
sorting of EGFR towards its lysosome-mediated degradation
[26,29,33,37]. We investigated whether the higher EGFR
turnover rate in 786-VHL cells was mostly due to increased c-
Cbl activity toward EGFR in these cells. To test this, we infected
786-VHL cells with shRNA constructs expressing either a control
sequence (SCR) or c-Cbl-1404, which successfully down-regulat-
ed the expression of c-Cbl (Fig. 4A). After drug selection of
polyclonal cells stably expressing these constructs, we compared
the half-lives of activated EGFR in these cells. If elevated c-Cbl
activity in 786-VHL cells was mostly responsible for the
enhanced turnover of activated EGFR, then depletion of c-Cbl
in these cells should prolong the half-life of activated EGFR to
that of 786-mock cells. We observed, however, the opposite: loss
of c-Cbl did not significantly change the 2 h half-life of activated
EGFR in 786-VHL cells (Fig. 4A and 4C). Western blotting with
an antibody that detected EGFR phosphorylated on tyrosine
1068 did show that loss of c-Cbl very moderately increased the
overall levels of active EGFR before and after EGF stimulation
(Fig. 4A). In VHL-deficient 786-mock cells, however, c-Cbl
suppression essentially prevented the degradation of the already
more stable EGFR: 786-mock SCR, EGFR half-life .4h ;
Figure 2. HIF was not the only factor stabilizing activated EGFR in VHL-deficient ccRCC cells. A. Western blot analysis of 786-VHL and
786-mock cells stably expressing shRNA constructs. For HIF2a and HIF1b analysis, nuclear extracts were generated and analyzed. Anti-HA blot
detected HA-VHL. B. 786-VHL cells expressing SCR (control), HIF2a-566 and HIF2a-1631 (shRNA constructs against HIF2a) were treated with EGF and
analyzed as described in Fig. 1A. C. 786-mock cells expressing SCR (control sequence), HIF2a-566 and HIF2a-1631 (shRNA constructs against HIF2a)
were treated with EGF and analyzed as described in Fig. 2B. D. The EGFR signals in Fig. 2B and 2C were normalized over Vinculin via densitometry and
plotted over time. Means and SDs of three separate experiments were shown.
doi:10.1371/journal.pone.0023936.g002
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during the experiment (Fig. 4B and 4C). After EGF stimulation,
neither the EGFR nor the phospho-EGFR levels decreased in
VHL-deficient cells during the experiment (Fig. 4B). This
suggested that c-Cbl hyperactivity was unlikely the reason that
activated EGFR was degraded faster in VHL-expressing cells,
and c-Cbl and pVHL collaborated to down-regulate the activated
EGFR. To ensure that the results were not caused by off-target
effects of c-Cbl-1404, we repeated the experiment with another
construct, c-Cbl-2901, which was equally effective against c-Cbl.
We obtained very similar results (Fig. 4D, 4E, and 4F), suggesting
that the off-target effects of shRNA were not the cause of the
observed results.
pVHL promoted c-Cbl-independent poly-ubiquitylation
of the activated EGFR
As stated before, it is controversial as to whether activated
EGFR is poly-ubiquitylated upon EGF stimulation [29,33,34,35].
In previous publications, ubiquitylation of activated EGFR was
analyzed in the absence of proteasome inhibitor. As proteins
conjugated with poly-ubiquitin chains except lys-63-linked chain
were quickly cleared by the proteasome [43], we hypothesized that
the poly-ubiquitylated EGFR signals may be more readily
visualized if proteasome function was disabled. To investigate
whether pVHL promotes the poly-ubiquitylation of activated
EGFR, we first tested the specificities of anti-ubiquitin (Ub)
antibodies against free Ub and Poly-Ub with western blots. As
Figure 3. Proteasome inhibitors prevented degradation of activated EGFR in both 786-VHL and 786-mock cells, while lysosome
inhibitors only stabilized activated EGFR in 786-mock cells. A. 786-VHL and 786-mock cells were treated with either lysosome inhibitors
(NH4Cl or Chloroquine) for twenty-four hours or proteasome inhibitors (MG132 or Bortezomib) for two hours. The lysates were analyzed with
indicated antibodies. Anti-HA blot detected HA-VHL. Analysis of half-lives of activated EGFR in 786-VHL and 786-mock cells: with no pretreatment (B)
and its graphic representation (C), pretreated with NH4Cl (D) and its graphic representation (E), pretreated with Chloroquine (F) and its graphic
representation (G), pretreated with MG132 (H) and its graphic representation (I), pretreated with Bortezomib (J) and its graphic representation (K).
* P,0.05; ** P,=0.001.
doi:10.1371/journal.pone.0023936.g003
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free Ub and Poly-Ub, while anti-Ub (FK-1) only detected Poly-Ub
(Fig. 5A) [29]. We then treated 786-VHL and 786-mock cells with
DMSO or MG132 for two hours before EGF stimulation. The
lysates were then immunoprecipitated with anti-EGFR antibody
before blotting with an anti-Ub antibody (Ubi-1). Activated EGFR
Figure 4. c-Cbl suppression only significantly stabilized activated EGFR in VHL-deficient cells but not in VHL-expressing cells. A.
786-VHL cells stably expressing either a control shRNA sequence (SCR) or c-Cbl-1404 were treated with EGF and analyzed with indicated antibodies as
described in Figure 1A. Anti-pY-EGFR detected phospho-tyrosine 1086 on EGFR. Anti-HA blot detected HA-VHL. B. 786-mock cells stably expressing
either SCR or c-Cbl-1404 were treated with EGF and analyzed with indicated antibodies as described in Figure 4A. C. The EGFR signals in Fig. 4A and
4B were normalized over Vinculin signals via densitometry and plotted over time. Means and SDs of three separate experiments were shown.
* P,0.05; ** P,=0.001. D. 786-VHL cells stably expressing either SCR or c-Cbl-2901 were treated with EGF and analyzed with indicated antibodies as
described in Figure 4A. E. 786-mock cells stably expressing either SCR or c-Cbl-2901 were treated with EGF and analyzed with indicated antibodies as
described in Figure 4A. F. Graphic representation of Fig. 4D and 4E. * P,0.05; ** P,=0.001.
doi:10.1371/journal.pone.0023936.g004
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MG132-treated VHL-expressing cells, but not in DMSO treated
VHL-expressing cells or in DMSO or MG132 treated VHL-
deficient cells (Fig. 5B, first panel). Reprobing with another anti-
Ub antibody (P4D1) revealed that Ubi1-specific Ub signals were
quite different from the P4D1-specific Ub signals (Fig. 5B, first and
second panels). The P4D1-specifc Ub signals were present near
250KDa molecular weight marker and were more focused, and
they were present in all the EGF stimulated samples. Furthermore,
the P4D1-specific Ub signals were enhanced by MG132 treatment
in VHL-expressing cells but not in VHL-deficient cells (Fig. 5B,
second panel). The anti-Ub blot of the lysates indicated that the
overall levels of ubiquitylation were not reduced in VHL-deficient
cells, so this did not cause the lack of Ubi-1-specific signals
associating with activated EGFR in these cells (Fig. 5B, fourth
panel). Our results suggested that pVHL promoted the ubiquityla-
tion of the activated EGFR.
Although only after the proteasome was inhibited the activated
EGFR associated with Ubi-1-specific Ub signals in VHL-
expressing cells, it was possible that the ubiquitylation occurred
on another protein that was tightly associated with EGFR rather
than on EGFR itself. If this were the case, boiling lysates with SDS
before EGFR immunoprecipitation should abolish the associated
Ub signals from EGFR. Indeed, this harsh treatment stripped
EGFR of non-covalently associated proteins such as c-Cbl
(Fig. S3A). Silver stain of immunoprecipitated EGFR under
Figure 5. pVHL promoted poly-ubiquitylation of the activated EGFR. A. 1 mg each of free ubiquitin and Poly-ubiquitin were resolved by SDS-
PAGE and detected by either commassie stain or indicated anti-Ub antibodies. B. 786-VHL and 786-mock cells were treated with EGF and were
starved of serum for two hours in the presence of DMSO (the solvent) or 10 mM MG132 before the addition of 30 ng/ml EGF. The lysates were
prepared with EBC buffer at indicated time and immunoprecipitated with anti-EGFR antibody. The immunoprecipitates were blotted with anti-Ub
(Ubi), anti-Ub (P4D1), and anti-EGFR sequentially with membrane stripping between blots. The lysates were blotted with indicated antibodies. C. 786-
VHL and 786-mock cells were treated with EGF and were starved of serum for two hours in the presence of DMSO (the solvent) or 10 mM MG132
before the addition of 30 ng/ml EGF. Denaturing IP was performed with anti-EGFR antibody with these lysates. The immunoprecipitates were blotted
with anti-Ub (FK-1), anti-Ub (P4D1), and anti-EGFR sequentially with membrane stripping between blots. The lysates were blotted with indicated
antibodies.
doi:10.1371/journal.pone.0023936.g005
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ing IP recovered mostly the antibody and EGFR itself but
removed the associating proteins (Fig. S3B). Anti-Ub (Ubi-1) and
anti-Poly-Ub (FK-1) blots of immunoprecipitated EGFR under
non-denaturing and denaturing conditions showed that under
both conditions, the Ub signals associated with activated EGFR
were much stronger in VHL-expressing cells than that in VHL-
deficient cells (Fig. S4A and S4B). This suggested that the Ub
signals were very tightly, possibly covalently, linked to the
activated EGFR in these cells.
Because Ubi-1 and P4D1 were not specific to Poly-Ub, and
EGFR was reported to be both mono-ubiquitylated and poly-
ubiquitylated, it was not known whether pVHL promoted the
poly-ubiquitylation of the activated EGFR. To address this, EGFR
was immunoprecipitated from 786-VHL and 786-mock cells
treated with DMSO or MG132 before EGF stimulation under
denaturing condition. Anti-Poly-Ub (FK-1) blot revealed that
Poly-Ub signals only associated with activated EGFR in VHL-
expressing cells but not in VHL-deficient cells, and only after the
proteasome function was inhibited (Fig. 5C).
c-Cbl is the major E3 ubiquitin ligase for activated EGFR and it
was not known whether the pVHL promoted ubiquitylation of
EGFR was c-Cbl-dependent. To address this, c-Cbl expression in
786-VHL and 786-mock cells were suppressed by stable
expression of c-Cbl-1404 shRNA construct. Cells expressing
SCR or c-Cbl-1404 were stimulated with EGF, then the lysates
were immunoprecipitated with anti-EGFR antibody. Anti-Ub
(P4D1) blot revealed that EGFR associated P4D1-specific Ub
signals disappeared after c-Cbl suppression in both 786-VHL and
786-mock cells (Fig. 6A and 6B, second panels), suggesting that c-
Cbl depletion did impact EGFR ubiquitylation. However, the high
molecular weight Ub signals associated with activated EGFR in
VHL-expressing cells persisted after c-Cbl depletion (Fig. 6A, first
panel), suggesting that pVHL-promoted EGFR ubiquitylation was
c-Cbl-independent. Repeating the same experiment with anti-
Poly-Ub (FK-1) with denaturing IP confirmed the above
conclusion (Fig. 6B).
Because the anti-Ub (P4D1) signals associated with EGFR was c-
Cbl-dependent and were more focused near 250 KDa, and c-Cbl
depletion seemed to remove the bottom half of Ubi-1-specific Ub
signals (Fig. 6A, first panel), we investigated whether these anti-Ub
antibodies detected different populations of Ub signals. Activated
EGFR from VHL-expressing cells was immunoprecipitated under
denaturing condition and run on a gel for a long time for better
resolution. Ubi-1-specific Ub signal mostly overlapped with
modified EGFR (Fig. 6C). P4D1-specific Ub signal overlapped
with the bottom half of Ubi-1-specific Ub signal, while the Poly-Ub
(FK-1) signal overlapped with the top half of Ubi-1-specific Ub
signals. There was little overlap between P4D1-specific Ub signal
and FK-1 Poly-Ub signal (Fig. 6C). This suggested that while Ubi-1
was detecting all forms of ubiquitin, P4D1 and FK-1 had high
affinity to different sub-populations of ubiquitin.
Discussion
VHL inactivation is a causal factor for the development of the
ccRCC tumors. Loss of pVHL functions leads to constant
activation of the HIF transcriptional factor. Blockage of tumor
angiogenesis, one of the consequences of HIF activation, produces
positive clinical outcomes [18]. VHL loss also causes abnormal
activation of EGFR, a receptor tyrosine kinase whose uncurbed
activity is oncogenic in many types of cancers.
After VHL loss, activated HIF up-regulates the expression of the
EGFR agonist TGF-a [19] and enhances the translational
efficiency of EGFR [20] to promote autonomous growth of
VHL-defective ccRCC cells. Recently it was reported that
degradation of activated EGFR was impaired in VHL-defective
ccRCC cells, so that EGFR was left to promote proliferation and
block apoptosis much longer to enhance oncogenesis [36]. We
independently discovered the stabilization of activated EGFR in
VHL-defective ccRCC cells and wished to critically examine the
contribution of HIF and lysosome to pVHL-mediated EGFR
degradation. Wang et al found that over-expression of HIF2a in
VHL-expressing cells stabilized activated EGFR, which we also
observed. They also showed that either VHL suppression, or over-
expression of HIF2a, or hypoxia clearly delayed Rab5-mediated
endosome fusion. So without VHL, HIF2a accumulated and
repressed rabaptin-5 expression, and this led to delayed endosome
fusion and subsequently slower lysosome-mediated turnover of
activated EGFR. However, this mechanism would predict that
suppression of endogenous HIF2a in 786-mock cells would restore
the half-life of activated EGFR to that of 786-VHL cells. As this
was missing in their paper, we performed this experiment and
found that depletion of endogenous HIF2a in 786-mock cells did
not significantly reduce the half-lives of activated EGFR (Fig. 2C
and 2D). Furthermore, hypoxia mimetics that blocked proline
hydroxylases to induce endogenous HIF2a did not significantly
enhance EGFR half-lives either in VHL-expressing cells. Finally, if
impaired lysosome function was the major cause of increased half-
life of activated EGFR in VHL-deficient cells, then blocking
lysosome function in VHL-expressing cells should prolong the
EGFR half-life to the similar level as seen in VHL-deficient cells.
That was not what we observed (Fig. 3). Thus we concluded that
HIF was not the only factor stabilizing activated EGFR in VHL-
deficient cells.
Although lysosome inhibitors did not significantly stabilize the
activated EGFR in 786-VHL cells, they did further stabilize the
activated EGFR in VHL-deficient cells (Fig. 3). The proteasomal
inhibitors, on the other hand, blocked the degradation of activated
EGFR in both VHL-expressing and VHL-deficient cells (Fig. 3).
The evidence suggested that the lysosome function was critical for
degradation of activated EGFR in VHL-deficient cells, and the
increased proteasome-mediated degradation was the major reason
that activated EGFR had a shorter half-life in VHL-expressing
ccRCC cells.
Since c-Cbl is the major E3 that ubiquitylates the activated
EGFR, which leads to its lysosome-mediated destruction, we
studied the contribution of c-Cbl to the EGFR turnover in ccRCC
cells. Suppression of c-Cbl expression did not significantly increase
the stabilities of the activated EGFR in VHL-expressing cells.
However, c-Cbl loss made the activated EGFR very stable in
VHL-deficient cells (Fig. 4). As the effects of c-Cbl suppression on
EGFR stability in ccRCC cells were very similar to that of
lysosome inhibitors, this was consistent with the notion that c-Cbl-
mediated ubiquitylation of EGFR led to lysosome-mediated
degradation. Furthermore, c-Cbl collaborated with pVHL to
promote the degradation of activated EGFR. Without both,
EGFR was activated but remained stable.
It is controversial as to whether activated EGFR is poly-
ubiquitylated and whether poly-ubiquitylated EGFR is subjected
to proteasomal or lysosomal degradation. We suspected that
pVHL may promote poly-ubiquitylation of activated EGFR. We
indeed observed VHL-dependent poly-ubiquitylation of activated
EGFR but only when proteasome was inhibited (Fig. 5C),
suggesting that activated EGFR was quickly turned over by the
proteasome under normal conditions. The comparison of non-
denaturing IP and denaturing IP suggested that the VHL-
dependent Poly-ub was tightly, possibly covalently, linked to
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poly-ubiquitylation of activated EGFR was c-Cbl-independent
(Fig. 6A and 6B). As EGFR-associated P4D1-specific Ub signals
were c-Cbl-dependent (Fig. 6A and 6B), c-Cbl was reported to
mainly mono-ubiquitylate activated EGFR [29,33], and P4D1-
specific anti-Ub signal was below the Poly-Ub (FK-1) signal and
overlapped with the bottom of the Ubi-1-specific Ub signal
(Fig. 6C), it was possible that P4D1 was mainly detecting mono-
ubiquitylated EGFR. This certainly deserves further investigation.
In all, our evidence suggested that pVHL promoted poly-
ubiquitylation on the activated EGFR which likely led to
proteasome-mediated degradation.
Because we observed that (1) c-Cbl promoted P4D1-specific Ub
signals on activated EGFR; (2) VHL-dependent poly-ubiquitylation
Figure 6. pVHL-dependent ubiquitylation of activated EGFR was c-Cbl-independent. A. 786-VHL and 786-mock cells expressing either a
control shRNA sequence (SCR) or c-Cbl-1404 were starved of serum for two hours in the presence of 10 mM MG132 before the addition of 30 ng/ml
EGF. The lysates were prepared with EBC buffer at indicated time and immunoprecipitated with anti-EGFR antibody. The immunoprecipitates were
blotted with anti-Ub (Ubi-1), anti-Ub (P4D1), and anti-EGFR sequentially with membrane stripping between blots. The lysates were blotted with
indicated antibodies. B. 786-VHL and 786-mock cells expressing either a scramble shRNA sequence (SCR) or c-Cbl-1404 were starved of serum for two
hours in the presence of 10 mM MG132 before the addition of 30 ng/ml EGF. Denaturing IP was performed with anti-EGFR antibody with these
lysates. The immunoprecipitates were blotted with anti-Poly-Ub (FK-1), anti-Ub (P4D1), and anti-EGFR sequentially with membrane stripping between
blots. The lysates were blotted with indicated antibodies. C. 786-VHL cells were treated with MG132 and stimulated with EGF for 60 minutes.
Denaturing IP with anti-EGFR antibody was performed with the lysate. The immunoprecipitated material was split and run on SDS-PAGE gel for
extended time and blotted with indicated antibodies. Long: long exposure. Short: short exposure.
doi:10.1371/journal.pone.0023936.g006
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inhibitionhad very similar effectson EGFR stability inccRCC cells;
(4) proteasome inhibitors, not lysosome inhibitors, abolished the
EGFR stability differences in VHL-expressing and VHL-deficient
cells, it was likely that pVHL-containing E3 complex and c-Cbl
promoted different kinds of ubiquitylation on activated EGFR.
Further functional and biochemical investigation will help to resolve
this issue.
In total, our results suggest that a pVHL-dependent poly-
ubiquitylation and proteasomal degradation pathway plays a very
important role in suppression of EGFR activity through degradation
of activated EGFR. It will be interesting to investigate whether
similar pVHL-dependent regulation of EGFR occurs in other cell
types.ItwillalsobeinterestingtolearnwhetherpVHLdirectlybinds
to and promotes ubiquitylation of activated EGFR and what the
bindingsignalis,and whattypeofubiquitinchain pVHL-containing
E3 ubiquitin ligase complex is adding onto EGFR. As disruption of
ubiquitylation [37], blocking of proteasome functions by inhibitors
[41], or VHL loss [36] all resulted in EGFR accumulating at early
stages during endocytosis which led to the conclusion that these
events blocked the proper endosome transportation/sorting, it is
worth investigating how and where these trapped EGFR proteins
were eventually degraded by proteasome.
Materials and Methods
Cell culture
ccRCC cells such as 786-O and A498 with or without pCDNA3
based wild type HA-VHL were described previously [17]. After
transfection, the cells were treated with 1 mg/ml neomycin to kill
the cells that do not stably express the plasmids. After three passages
all the cells became drug-resistant. The VHL status and the HIF
activityofthecelllineswereconfirmedbyanti-HAandanti-GLUT1
immunoblots. Cell lines were maintained in glutamine-containing
DMEM medium with 10% Fetal Bovine Serum (FBS) plus 1%
penicillin and streptomycin. For Epidermal Growth Factor (EGF)
stimulation, sub-confluent cells with similar densities were washed
and starved in DMEM medium for two hours before addition of
EGF (Biovision, Mountainview, CA) to 30 ng/ml final concentra-
tion. At indicated time points, the cells were washed with PBS and
lysed with EBC buffer (50 mM Tris (pH 8), 120 mM NaCl, 0.5%
NP-40) containing protease inhibitor cocktail (Roche complete,
11836153001) and phosphatase inhibitor cocktail (final concentra-
tions: 5 mM sodium Fluoride, 1 mM sodium orthovanadate, 1 mM
sodium pyrophosphate, and 1 mM b-glycerophosphate).
For hypoxia mimetic treatment, 100 mM Deferoxamine (DFO,
an iron chelator that depletes iron at the active site of the prolyl
hydroxylases) or 100 mM Cobalt Chloride (CoCl2, which replaces
iron at the active site of the prolyl hydroxylases) was added to the
cell culture media for twenty-two hours before the cells were
starved and treated with EGF in the presence of the chemicals. For
cycloheximide (CHX) treatment, 70–80% confluent cells were
treated with CHX at 100 mg/ml for two hours while the cells were
starved and treated with EGF in the presence of CHX.
Analysis of EGFR stability in the absence or the presence
of lysosomal inhibitors or proteasome inhibitor
To inhibit the lysosomal function, lysosome inhibitors were added
to the 786-O cells with or without stably expressed HA-VHL and
incubated for twenty-two hours. Then the cells were starved of FBS
for two hours in the presence of lysosome inhibitors before the
addition of 30 ng/ml EGF. Final concentrations of inhibitors:
10 mM NH4Cl (Amresco, Solon,OH); 100 mMChloroquine(Sigma,
Saint Louis, MO). To inhibit the proteasomal function, the same cells
were starved of FBS for two hours in the presence of 10 mMM G 1 3 2
(Cayman Chemical, Ann Arbor, MI) or 50 nM Bortezomib (S1013)
(Sellick Chemicals, Houston, TX) before two-hour starvation and the
addition of EGF in the presence of the inhibitors.
Western Blot analysis
Total cellular lysates were prepared with EBC buffer (50 mM
Tris (pH 8), 120 mM NaCl, 0.5% NP-40). The protein concentra-
tionsofthe lysatesweredetermined bya proteinassaykit (500-0006)
from Bio-rad (Hercules, CA). NE-PER Nuclear and Cytoplasmic
Extraction Kit (Thermo Scientific, Rockford, IL, Cat# 78833) was
used to fractionate the cells according to manufacturer’s instruction.
In brief, the cells were trypsinized and precipitated before addition
of reagents CERI and CERII to extract the cytoplasmic proteins.
The remaining pellets were further added NER reagent and
vortexed to extract the nuclear proteins. The same amount of total
protein from each sample was boiled with sample buffer before
being resolved by SDS-PAGE and analyzed with standard western
blot techniques. The blots were developed with Super Signal Pico
substrate (Pierce Biotechnology, Rockford, IL) or Immobilon
Western substrate (Millipore, Billerica, MA). Antibodies against
EGFR (A300-387A, A300-388A) are from Bethyl Laboratories
(Montgomery, TX). Antibodies against phospho-EGFR (Tyr1086)
(3777), Phospho-Akt (Thr308) (2965), Akt (9272), Phospho-Erk (1/
2) (Thr202/Tyr204) (9101), Erk (1/2) (9102) were from Cell
Signaling Technology (Boston, MA). Antibodies against HIF2a
(NB100-480), HIF1b (NB100-124), GLUT1 (NB300-666) were
purchased from Novus Biologicals (Littleton, CO). Antibodies
against Cathepsin D (sc-6486), PARP1 (sc-7150), anti-HA-epitope
(sc-7392), anti-c-Cbl (sc-170), anti-Ub (P4D1) (sc-8017), and
Vinculin (sc-73614) were from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-Ub antibody (Ubi-1) (Mab1510) was from
Millipore (Billerica, MA), and anti-Poly-Ub antibody (FK1)
(D071-3) was from MBL (Nagoya, Japan). For sequential western
blots, the membranes were stripped with gentle review buffer
(Amresco, Solon, OH) between blots. The intensity of a band was
determined with NIH imageJ software (Wayne Rasband, National
Institutes of Health). Free Ub (BML-UW8795) was obtained from
Enzo Life Sciences (Plymouth meeting, PA), and Poly-Ub (Ub1-7,
K48-linked) (UC-240) was from BostonBiochem(Cambridge, MA).
For silver stain, the proteins were resolved by SDS-PAGE. Then
the gel was fixed with a mixture of 50% methanol and 5% acetic
acid. Then it was washed sequentially with 50% methanol and
water for ten minutes each. The gel was sensitized with 0.02%
sodium thiosulfate for one minute, rinsed twice with water, then
incubated with 0.1% silver nitrate at 4uC for twenty minutes. The
gel was rinsed twice with water, then developed with 0.04%
formalin in 2% sodium carbonate until the desired result was
achieved. The reaction was stopped by 5% acetic acid.
Short Hairpin RNAs (shRNAs)
shRNA constructs in E. coli glyceryl stock were obtained from





The DNA was purified with Maxi-prep kit (Qiagen, Valencia,
CA). Lentiviral plasmids were transfected into the Phoenix
packaging cell line using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
Tissue culture medium was collected 48 h after transfection,
passed through a 0.45-mm-pore-size filter, and added to cells in the
presence of 8 mg/ml polybrene. Two days later 1 mg/ml
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plasmids. After three passages in the presence of puromycin all the
cells became drug-resistant. The efficacy of the shRNA suppres-
sion was confirmed by western blot and/or real-time PCR before
the cells were used for experiments.
Denaturing and non-denaturing immunoprecipitation
786-O cells with or without stably expressed HA-VHL at about
80% confluence were starved with FBS-free medium containing
10 mM MG132 for two hours, then 30 ng/ml EGF was added and
the cells were harvested at the following time points: 0, 10 minutes,
60 minutes. The cells were lysed with EBC buffer containing
proteaseinhibitorcocktail and phosphataseinhibitor cocktail onice.
The lysates were sonicated for 15 seconds before centrifugation as
15,000 rpm for 10 minutes. The cleared supernatants were
transferred to new eppendorf tubes. After measurement of protein
concentrations, 3 mg total protein from each sample were used for
both non-denaturing IP and denaturing IP. For denaturing IP,
1.5 mg total protein was mixed with equal volume of 1% SDS
solution to reach a final concentration of 0.5% SDS. The mixtures
were heated for 5 minutes at 100uC. EBC buffer containing
protease inhibitor cocktail and phosphatase inhibitor cocktail was
added to dilute the SDS to 0.1% final concentration. Samples for
non-denaturing IP were not boiled with SDS before immunopre-
cipitation. To each sample, 1 mg anti-EGFR antibody was added
and the tubes were rotated at 4uC overnight. The mixtures were
centrifuged at 15,000 rpm for 10 minutes. The cleared lysates were
transferred to new tubes, and 20 ml protein A beads were added to
each sample. The mixtures were rotated for one hour at 4uC before
centrifugation at 7000 rpm for thirty seconds. The beads were
washed with NETN buffer (50 mM Tris-HCl pH 7.9, 100 mM
NaCl, 1 mM EDTA, 10% glycerol, 0.2% NP-40) for three times.
15 ml2 6 protein loading buffer were added to each tube. The
samples were boiled for five minutes at 100uC. The proteins were
resolved with SDS-PAGE gels before western blot analysis.
Statistical analysis
The western blot signals of EGFR and Vinculin were quantified
with NIH imageJ software. The EGFR/Vinculin ratios from three
different experiments were calculated and plotted over time as
means 6 standard deviation (SD). The ratios at t=0 were
artificially set as 1. Differences between the means of any two
samples at a given time of EGF treatment were evaluated by the
Unpaired t-test using the SigmaPlot program. P values ,0.05 were
considered statistically significant. *: P,0.05; **: P,=0.001.
Supporting Information
Figure S1 Activated EGFR had higher stability in VHL-
deficient ccRCC cells than in VHL-expressing ccRCC
cells in the presence of cycloheximide. A. Renal carcinoma
786-O cells transfected to produce wild type HA-VHL (786-VHL)
or with an empty plasmid (786-mock) were starved for two hours
in serum free DMEM media in the presence of 100 mg/ml
cycloheximide (CHX) before addition of 30 ng/ml EGF. Total cell
lysates were prepared at indicated time points and immunoblotted
with the indicated antibodies. B. The same experiment in Fig. S1A
was repeated with human renal carcinoma A498 cell lines with or
without HA-VHL.
(TIF)
Figure S2 Hypoxia mimetics did not significantly
increase the half-lives of activated EGFR in VHL-
expressing ccRCC cells. 786-VHL (A) and 786-mock (B) cells
were either untreated or treated with 100 mM hypoxia mimetics
(DFO or CoCl2) for twenty-two hours. Then the cells were starved
of serum for two hours in the absence or the presence of chemicals
before the addition of 30 ng/ml EGF. The lysates were prepared
with EBC buffer at indicated time and immunoblotted with
indicated antibodies. Anti-HA blots detected HA-VHL.
(TIF)
Figure S3 Denaturing IP removed proteins associated
with activated EGFR. A. 786-VHL and 786-mock cells were
starved and treated with 10 mM MG132 for two hours before
addition of EGF. EBC lysates were generated. Half of the lystates
were used for non-denaturing IP with anti-EGFR antibody, and
the other half used for denaturing IP. The immunoprecipitated
materials were blotted with indicated antibodies. B. A similar
experiment as described in S3A was performed and the
immunoprecipitated materials were resolved on a SDS-PAGE
gel before silver staining.
(TIF)
Figure S4 pVHL-dependent poly-ubiquitylation on the
activated EGFR persisted after denaturing IP. A. 786-
VHL and 786-mock cells expressing c-Cbl-1404 to avoid the
interference of P4D1-specific Ub signals were starved of serum for
two hours in the presence of 10 mM MG132 before the addition of
30 ng/ml EGF. The lysates were prepared with EBC buffer at
indicated time. Half of the lysates were used for non-denaturing IP
and the other half were used for denaturing IP. The immunoprecip-
itates were blotted with anti-Ub (Ubi-1) and anti-EGFR sequentially
with membrane stripping between blots. The lysates were blotted with
indicated antibodies. B. The same experiment as in S4A was
performed and the immunoprecipitates were blotted with anti-poly
Ub (FK-1) and anti-EGFR sequentially with membrane stripping
between blots. The lysates were blotted with indicated antibodies.
(TIF)
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